IL-4
Interleukin-4 (IL-4) is a critical Th2 cytokine that regulates immune responses by promoting differentiation of naive CD4+ T cells into Th2 cells[1]. Mechanistically, IL-4 activates the JAK-STAT6 signaling pathway, leading to transcriptional induction of genes involved in humoral immunity, including IgE class switching in B cells[1]. In disease models, IL-4 contributes to the pathogenesis of allergic inflammation and asthma by inducing eosinophilia, mucus hyperproduction, and alternatively activated macrophages[1]. Compared with related isoforms such as IL-13, IL-4 exhibits unique receptor engagement, preferentially signaling through IL-4Rα paired with the common gamma chain, which defines distinct cellular responses[1]. IL-4 agonists and inhibitors have been applied in experimental research to modulate Th2-skewed immune responses, enabling the study of allergic airway inflammation and potential therapeutic interventions[1]. Experimental blockade of IL-4 reduces IgE production and airway hyperreactivity, confirming its central role in type 2 immunity and providing a framework for targeted immunomodulation in preclinical models[1]. Therefore, IL-4 serves as both a mechanistic marker and a modifiable factor in studies of cytokine-driven inflammation.
-
IL-4 Related Products (89)
Related Products (89)
-
Recombinant Proteins (26)
-
Antibodies (1)
-
(S,S)-Formoterol
0 ImagesCat. No.: HY-B0010CCAS No.: 67346-48-9Synonyms: (+)-Formoterol(S,S)-Formoterol ((+)-Formoterol) is the (S,S)-enantiomer of Formoterol (HY-B0010B). (S,S)-Formoterol is a β2-adrenergic receptor (β2-adrenergic receptor) ligand. (S,S)-Formoterol can induce mast cell mediator release, peribronchial and perivascular inflammatory cell infiltration, basal airway tone, IFN-γ production, and IL-4 production. (S,S)-Formoterol acts through the β2-adrenergic receptor, altering its transduction pathways and modulating receptor structure and function. (S,S)-Formoterol can be used in the study of asthma.
-
(14S,15R)-14-Deoxyoxacyclododecindione
0 ImagesCat. No.: HY-162404CAS No.: 1899061-36-9(14S,15R)-14-Deoxyoxacyclododecindione (Compound 3) acts as an inhibitor of TGF-β-dependent Smad2/3 and IL-4-dependent STAT6, with IC50 values of 90 nM and 20 nM, respectively. (14S,15R)-14-deoxyoxacyclododecindione is a potent IL-4 inhibitor with an IC50
value of 20 nM. (14S,15R)-14-Deoxyoxacyclododecindione is applicable to the research of chronic inflammation and fibrotic diseases.
-
Epinastine hydrochloride (Standard)
0 ImagesSynonyms: WAL801 hydrochloride (Standard)Epinastine (hydrochloride) (Standard) is the analytical standard of Epinastine hydrochloride (HY-B0640A). This product is intended for research and analytical applications. Epinastine hydrochloride (WAL801 hydrochloride) is a selective and orally active histamine H1 receptor antagonist, CD96/PVR inhibitor and mast cell stabilizer. Epinastine hydrochloride has high affinity for neuronal octopamine receptors in locusts (Ki = 2 nM) and honeybees (Ki = 1.1 nM). Epinastine hydrochloride inhibits TARC, IL-8, and IL-4. Epinastine hydrochloride activates anti-colon cancer immunity and inhibits Substance P (HY-P0201)-induced scratching behavior and increased vascular permeability. Epinastine hydrochloride can be used in the research of allergic diseases.
-
C6 L-threo Ceramide
0 ImagesCat. No.: HY-116609CAS No.: 189894-80-2
-
PI3Kδ-IN-28
0 ImagesCat. No.: HY-184125PI3Kδ-IN-28 is an orally active and selective PI3Kδ inhibitor with an IC50 of 6.1 nM. PI3Kδ-IN-28 inhibits pro-inflammatory M1 macrophage polarization, promotes anti-inflammatory M2 phenotype, and alleviates pulmonary edema and inflammatory infiltration. PI3Kδ-IN-28 is applicable to research related to acute lung injury.
-
MR-39
0 ImagesCat. No.: HY-184654CAS No.: 2169267-60-9MR-39 is a FPR2 agonist (EC50 = 3.9 μM). MR-39 activates FPR2 to promote neuroinflammation resolution (downregulates IL-1β and TNF-α, modulates NF-κB), upregulates synaptic proteins (synaptic proteins) and improves dendritic spine morphology. MR-39 inhibits MAPK/ERK and AKT phosphorylation in glioblastoma, induces S-phase arrest, and suppresses migration, angiogenesis, and hypoxic adaptation. MR-39 reduces Aβ plaque burden via inhibiting MyD88/NF-κB and NLRP3 inflammasome. MR-39 can be used for research on autism spectrum disorder, Alzheimer's disease, and glioblastoma.
-
IAV-IN-5
0 ImagesCat. No.: HY-183313CAS No.: 3038861-11-6IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis, oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection.
-
PARP14 inhibitor 1
0 ImagesCat. No.: HY-172806CAS No.: 3035493-13-8PARP14 inhibitor 1 is an orally active, selective PARP14 inhibitor with an IC50 of 5.52 nM. PARP14 inhibitor 1 exhibits favorable pharmacokinetic properties and in vivo safety. PARP14 inhibitor 1 enhances and stabilizes intracellular endogenous PARP14 protein levels, while effectively reducing the expression levels of IL-4, IL-13 and IL-17A. PARP14 inhibitor 1 can be used in research related to atopic dermatitis.
-
S-palm P0(180–199)
0 ImagesCat. No.: HY-P10441CAS No.: 1240687-76-6S-palm P0(180-199) is an S-palmitoylated peptide derived from P0 protein. S-palm P0(180-199) induces IL-17+ cells, macrophage infiltration, and anti-P0 antibodies. S-palm P0(180-199) induces chronic inflammatory demyelinating polyneuropathy in rats via active immunization, manifesting as a relapsing-remitting disease driven by persistent T cells, macrophages, Th17 cells and related cytokines, and P0-specific IgG. S-palm P0(180-199) can be used in research related to chronic inflammatory demyelinating polyneuropathy.
-
Anti-Influenza agent 12
0 ImagesCat. No.: HY-189215CAS No.: 3087067-85-1Anti-Influenza agent 12 is an orally active inhibitor of influenza A virus infection. Anti-Influenza agent 12 inhibits RIG-I-mediated innate immune signaling and TLR3-mediated signaling pathways. Anti-Influenza agent 12 inhibits NF-κB phosphorylation and downregulates the expression levels of IRF3, ASC, iNOS, IL-4, IL-6, and IFN-α inflammatory genes. Anti-Influenza agent 12 inhibits viral nucleoprotein (NP) and matrix protein 2 (M2) mRNA transcription and protein synthesis. Anti-Influenza agent 12 inhibits virus-induced apoptosis, reduces ROS and NO production, and maintains mitochondrial membrane potential. Anti-Influenza agent 12 exhibits broad-spectrum activity against H1N1 and H3N2 subtypes, reduces viral load, and alleviates lung tissue damage. Anti-Influenza agent 12 can be used for research on influenza A virus infection.
-
STAT6-IN-7
0 ImagesSTAT6-IN-7 is a STAT6 inhibitor. STAT6-IN-7 exhibits an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. STAT6-IN-7 can be used in the research of atopic dermatitis.
-
F8-IL-4
0 ImagesCat. No.: HY-P992000F8-IL-4 is an immune cytokine targeting IL-4. F8-IL-4 specifically delivers IL-4 to inflammatory sites via binding to targets expressed on neovascular vessels. F8-IL-4 alleviates collagen-induced arthritis in mice by regulating T cell subsets and macrophage polarization. When combined with Dexamethasone (HY-14648), F8-IL-4 produces a synergistic and long-lasting therapeutic effect, and prevents arthritis recurrence after drug withdrawal by maintaining anti-inflammatory cell phenotypes and cytokine profiles. F8-IL-4 can be used in the research of collagen-induced arthritis.
-
PKR1 antagonist-2
0 ImagesCat. No.: HY-153201CAS No.: 910113-34-7PKR1 antagonist-2 is a non-peptide prokineticin receptor antagonist that preferentially binds to and blocks PK-R1 signaling while also blocking PK-R2. PKR1 antagonist-2 shifts the autoimmune response against myelin from a Th1/Th17 profile toward a Th2 profile, reducing myelin antigen-specific T cell proliferation and the production of proinflammatory cytokines (IFN-γ, TNF, IL-6, IL-17), and increasing the levels of anti-inflammatory cytokines IL-4/IL-10. PKR1 antagonist-2 significantly alleviates disease severity in relapsing-remitting and chronic experimental autoimmune encephalomyelitis (EAE). PKR1 antagonist-2 can be used in research related to multiple sclerosis .
-
VAK-694
0 ImagesCat. No.: HY-P992480
-
Altrakincept
0 ImagesCat. No.: HY-P992150Altrakincept is a recombinant hIL-4 receptor and IL-4 neutralizer. Altrakincept neutralizes endogenous IL-4, and prevents the decline of pulmonary function and acute asthma exacerbations after abrupt withdrawal of inhaled glucocorticoids.
-
STAT6-IN-12
0 ImagesCat. No.: HY-162405CAS No.: 2949393-27-3STAT6-IN-12 is a potent STAT6 inhibitor with an IC50 of 50 nM. STAT6-IN-12 also inhibits Smad2/3 with an IC50 of 68 nM. STAT6-IN-12 inhibits TGFβ-dependent Smad2/3 signaling pathway, IL-4-dependent STAT6 signaling pathway, and cellular inflammatory responses. STAT6-IN-12 can be used for the research of inflammation.
-
IL-4-IN-3
0 ImagesCat. No.: HY-187161CAS No.: 3104023-25-5IL-4-IN-3 (Compound 15/analog 15) is a selective, reversible small-molecule IL-4 inhibitor with a Kd of 31.9 nM for IL-4. IL-4-IN-3 inhibits IL-4-induced STAT6 phosphorylation in THP-1 monocytes and Ramos B lymphocytes. IL-4-IN-3 can be used in research related to allergic inflammation, cancer, autoimmune diseases, asthma and arthritis.
-
PDE4-IN-8
0 ImagesCat. No.: HY-144684CAS No.: 2415085-45-7PDE4-IN-8 (Example 5) is a potent PDE4 inhibitor with an IC50 of 0.93 nM for PDE4B2.PDE4-IN-8 has little effect on IL13 (IC50=4.04 nM), IL4 (IC50=36.33 nM), IFNy (IC50=2394 nM).
-
AVP-13358
0 ImagesCat. No.: HY-165484CAS No.: 459805-03-9AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses.
-
GNE-7056
0 ImagesCat. No.: HY-189477CAS No.: 1557236-81-3GNE-7056 is an orally active interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.2 nM against human kinase, and exhibits high selectivity over LCK kinase. GNE-7056 inhibits PLCγ-1 phosphorylation, suppresses the production of IL-2, IL-4, IL-13 and TH2 cytokines, reduces CD4+ T-cell proliferation, and inhibits activation-induced cell death of CD4+ T cells by decreasing the abundance of FasL. GNE-7056 can be used in asthma-related research.
